Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

By J. Mchutchison, M. Manns, K. Patel, T. Poynard, K. Lindsay, C. Trépo, J. Dienstag, William M. Lee, Carmen Mak, J. Garaud and 1 more. Gastroenterology, 2002

1,055 citations recorded by the source corpus.

Subfields: Family Practice, Hepatology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/2ea32c0c11c9fc773a8408ff4d97cd4f120d9487

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Sugiyama
2. M. Kurosaki
3. M. Mizokami
4. Yasuhito Tanaka
5. N. Nishida
6. M. Honda
7. N. Izumi
8. K. Matsuura

Citations in the corpus

• Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C (2009, background): “As a reduction in the dose of PEG-IFN-α and RBV can contribute to a less sustained virological respons”
• Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. (2014, neutral): “Diarrhea 24 (11) 18 (8) 24 (11) 14 (6)”
• EASL Clinical Practice Guidelines: management of hepatitis C virus infection. (2011, background): “It is recommended that any dose reductions are reviewed and a full dose reinstated as soon as possible to attain and sustain maximum exposure to each drug [110].”